Boulder – January20, 2023 –Cooley advised Inscripta, a global leader in genome engineering technology, on its acquisition of Infinome Biosciences and Sestina Bio. Partner Mike Nelson led the Cooley team.
These acquisitionsadvance Inscripta's strategy to develop and commercialize biomanufactured products for a broad spectrum of industrial and consumer markets.They also demonstrate Inscripta's confidence in the commercial potential of the bioeconomy and the power of genome engineering to accelerate biomanufacturing innovation
Inscripta is a life science technology company committed to creating a cleaner, healthier and more sustainable world through biomanufacturing.Itfocuses onthe continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing and spur new, safeand secure biotech innovations
With these deals, Cooley continues to strengthen its presence in Colorado. In 2022, Cooley advised ColdQuanta on its $110 million Series B funding, and the company was featured on Time magazine's Best Inventions of 2022 list.